CEOS.US CeCors Inc
- Market cap
- USD 1.17M
- P/E
- -
- P/B
- -
- ROE
- -112.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.
Is CEOS.US undervalued?
Graham numberThe Graham number of CeCors Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CeCors Inc fundamental analysis
No fundamental analysis for CeCors Inc yet.
CeCors Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CeCors Inc
Psykey, Inc. engages in the research, development, and commercialization of entheogenic, adaptogenic, and nootropic ingredients and formulations for its functional product lines. The company also engages in the development of technologies for the composition, bioavailability, and targeted delivery of entheogen-based therapeutics for the psychedelic market. Its retail products include functional mushroom coffees and teas, oral supplements, and single serve drink mixes. The co…
Full company profileCeCors Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CeCors Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.54M | 1.54K | 1.54K | - | - | - | 19.3K | 419K | 6.28M | - | - |
| Gross Profit | 603K | 602.80 | 603.00 | -6.00 | - | - | 11.3K | 416K | 6.26M | - | - |
| Operating Income | -632K | -662.00 | -730.00 | -4.34K | - | -332K | -356K | -798K | -320K | -1.96M | -1.17M |
| EBITDA | -570K | -656.00 | -660.00 | -4.33K | - | -332K | -356K | -1.30M | -298K | -1.96M | -1.17M |
| Net Income | -602K | -631.60 | -696.00 | -4.36K | - | -344K | -498K | -1.32M | -351K | 3.12M | -1.64M |
| EPS | -0.01 | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | -0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 995K | 131K | 209K | 209K | - | 627K | 575K | 1.73M | 4.12M | 3.65M | 3.23M |
| Total Liabilities | 4.54M | 4.57K | 4.79K | 4.79K | 4.79K | 988K | 1.39M | 2.47M | 5.14M | 1.78M | 1.77M |
| Shareholders' Equity | -3.54M | 126K | 205K | 205K | -4.79K | -362K | -814K | -747K | -1.02M | 1.87M | 1.46M |
| Cash & Short-term Investments | -1.00K | - | 0.30 | 0.30 | - | 71.3K | 3.44K | 376K | 2.27M | 546K | 2.57M |
| Total Debt | 3.90M | 3.93K | 3.93K | 3.93K | - | 510K | 1.32M | 1.01M | 1.22M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -733K | -763.00 | -602.00 | -4.36K | 157.00 | -92.3K | -92.9K | 160K | 2.13M | 1.05M | -1.71M |
| Capital Expenditure | 0.00 | 3.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 160K | 78.7K | 3.00 | 0.00 |
| Free Cash Flow | -733K | -760.00 | -602.00 | -4.36K | 157.00 | -92.3K | -92.9K | 160K | 2.05M | 1.05M | -1.71M |
| Ratios | |||||||||||
| ROE | - | -0.5% | -0.3% | -2.1% | - | - | - | - | - | 166.8% | -112.1% |
| ROA | -60.5% | -0.5% | -0.3% | -2.1% | - | -54.8% | -86.6% | -76.6% | -8.5% | 85.5% | -50.8% |
| Net Profit Margin | -39.0% | -40.9% | -45.1% | - | - | - | -2,576.9% | -315.8% | -5.6% | - | - |
| Debt to Equity | - | 0.03x | 0.02x | 0.02x | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
CeCors Inc dividends
CeCors Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Aug 26, 2008.
Who owns CeCors Inc
Ownership data of CeCors Inc is not available yet.
CeCors Inc company profile
- Company name
- CeCors Inc
- Ticker
- CEOS.US
- Exchange
- USA Stocks
- Sector
- Consumer Defensive
- Industry
- Health Care Equipment & Supplies
- Employees
- 6
- Fiscal year end
- December
- Address
- 17 Belfield Road, Toronto, ON, Canada, M9W1E8
- Phone
- 888 376 8258
- Website
- psykeyworld.com
About CeCors Inc
Psykey, Inc. engages in the research, development, and commercialization of entheogenic, adaptogenic, and nootropic ingredients and formulations for its functional product lines. The company also engages in the development of technologies for the composition, bioavailability, and targeted delivery of entheogen-based therapeutics for the psychedelic market. Its retail products include functional mushroom coffees and teas, oral supplements, and single serve drink mixes. The company was formerly known as CeCors, Inc. and changed its name to Psykey, Inc. in August 2021. The company was incorporated in 2002 and is based in Toronto, Canada.
CeCors Inc management
5- Mr. Michael MaherInterim Chief Executive Officer
- Mr. Guy Patrick RatchfordPresident, Secretary, Acting Principal Executive, Financial and Accounting officer & Director
- Mr. Mark PerkellVice President and General Counsel
- Jacqueline Rae DanforthCompliance Officer & Accountant
- Mr. John GustinHead of Global Business Development